Literature DB >> 32829671

Adeno-Associated Virus Vector Mobilization, Risk Versus Reality.

Liujiang Song1,2, R Jude Samulski1,3, Matthew L Hirsch1,2.   

Abstract

Recombinant adeno-associated viral (rAAV) vector mobilization is a largely theoretical process in which intact AAV vectors spread or "mobilize" from transduced cells and infect additional cells within, or external of, the initial host. This process can be helper virus-independent (vector alone) or helper virus-dependent (de novo rAAV production facilitated by superinfection of both wild-type AAV [wtAAV] and Adenovirus 5 [Ad] helper virus). Herein, rAAV production and mobilization with and without wtAAV were analyzed following plasmid transfection or viral transduction utilizing well-established in vitro conditions and analytical measurements. During in vitro production, wtAAV produced the highest titer with rAAV-luc (4.1 kb), rAAV-IDUA (3.7 kb), and rAAV-Nano-dysferlin (4.9 kb) generating 2.5-, 5.9-, or 10.7-fold lower amounts, respectively. Surprisingly, cotransfection of a wtAAV and an rAAV plasmid resulted in a uniform decrease in production of wtAAV in all instances with a concomitant increase of rAAV such that wtAAV:rAAV titers were at a ratio of 1:1 for all constructs investigated. These results were shown to be independent of the rAAV transgenic sequence, size, transgene, or promoter choice and point to novel aspects of wtAAV complementation that enhance current vector production systems yet to be defined. In a mobilization assay, a sizeable amount of rAAV recovered from infected 293 cell lysate remained intact and competent for a secondary round of infection (termed Ad-independent mobilization). In rAAV-infected cells coinfected with Ad and wtAAV, rAAV particle production was increased >50-fold compared with no Ad conditions. In addition, Ad-dependent rAAV vectors mobilized and resulted in >1,000-fold transduction upon a subsequent second-round infection, highlighting the reality of these theoretical safety concerns that can be manifested under various conditions. Overall, these studies document and signify the need for mobilization-resistant vectors and the opportunity to derive better vector production systems.

Entities:  

Keywords:  adeno-associated virus; adenovirus; gene therapy; mobilization; vector

Year:  2020        PMID: 32829671      PMCID: PMC7585609          DOI: 10.1089/hum.2020.118

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  81 in total

1.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Authors:  Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2017-07-14       Impact factor: 79.321

2.  Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates.

Authors:  Knut Stieger; Josef Schroeder; Nathalie Provost; Alexandra Mendes-Madeira; Brahim Belbellaa; Guylène Le Meur; Michel Weber; Jack-Yves Deschamps; Birgit Lorenz; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

3.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells.

Authors:  J D Tratschin; I L Miller; M G Smith; B J Carter
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

5.  The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection.

Authors:  D J Pereira; D M McCarty; N Muzyczka
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production.

Authors:  J M Allen; D J Debelak; T C Reynolds; A D Miller
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells.

Authors:  R J Samulski; K I Berns; M Tan; N Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

Review 8.  An inventory of shedding data from clinical gene therapy trials.

Authors:  Ellen A M Schenk-Braat; Marjolein M K B van Mierlo; Gerard Wagemaker; Chris H Bangma; Leonie C M Kaptein
Journal:  J Gene Med       Date:  2007-10       Impact factor: 4.565

9.  Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus.

Authors:  Jarrod S Johnson; R Jude Samulski
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

10.  Preparation and Administration of Adeno-associated Virus Vectors for Corneal Gene Delivery.

Authors:  Liujiang Song; Jacquelyn J Bower; Matthew L Hirsch
Journal:  Methods Mol Biol       Date:  2020
View more
  1 in total

1.  [Prokaryotic expression of a recombinant protein of adeno-associated virus capsid conserved regions and preparation of its polyclonal antibody].

Authors:  S Li; C Cao; H Zhang; Y Li; X Zhang; Z Yang; Y Xia; L Wang; Y Lü
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.